Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxin Danshen Dropping Pill in post-PCI coronary heart disease patients with anxiety or depression
ChiCTR1800014291Phase 4Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Aug 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of Guanxin Danshen Dripping Pills in coronary arteriosclerosis, anxiety disorder and major depressive disorder (MDD) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Improvement in anxiety and depression symptoms and Heart rate variability. Started Aug 2017; status: recruiting.
02
Drugs
Guanxin Danshen Dripping Pills
03
Conditions
coronary arteriosclerosisanxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR1800014291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014291.